CTSK: Key Regulator of Cell-Cell Adhesion and Potential Drug Targets

Target Name: CTSK

NCBI ID: G1513

CTSK

CTSK: Key Regulator of Cell-Cell Adhesion and Potential Drug Targets

CTSK (Cadherin-Tissue Survival Factor-K) is a protein that is expressed in various tissues throughout the body, including epithelial, endothelial, and mesenchymal tissues. It is a key regulator of cell-cell adhesion and has been implicated in a number of diseases, including cancer.

One of the main functions of CTSK is its role in cell-cell adhesion. CTSK is a transcription factor that can induce the expression of genes involved in cell-cell adhesion, such as cadherins and tight junctions. These genes are important for maintaining tissue structure and function, and are critical for the development and maintenance of tissues such as skin, heart, and lungs.

In addition to its role in cell-cell adhesion, CTSK is also involved in a number of other processes that are important for tissue growth and development. For example, CTSK has been shown to play a role in the regulation of cell proliferation and differentiation, and has been implicated in the development of cancer.

One of the challenges in studying CTSK is its complex structure and the fact that it is expressed in a wide variety of tissues. However, research into CTSK has identified a number of potential drug targets and biomarkers that may be useful for the development of new treatments for a variety of diseases.

One potential drug target for CTSK is its role in the regulation of cell-cell adhesion. Researchers have identified a number of drugs that can inhibit the activity of CTSK, including inhibitors of protein tyrosine kinase (PTK), which is a signaling pathway that is involved in the regulation of cell-cell adhesion. These drugs have been shown to be effective in treating a variety of diseases, including cancer.

Another potential drug target for CTSK is its role in the regulation of cell proliferation and differentiation. Researchers have identified a number of drugs that can inhibit the activity of CTSK, including inhibitors of the protein kinase B (PKB), which is involved in the regulation of cell proliferation. These drugs have been shown to be effective in treating a variety of diseases, including cancer.

In addition to its potential drug targets, CTSK is also a potential biomarker for a variety of diseases. For example, CTSK has been shown to be elevated in a variety of cancer tissues, and has been used as a biomarker for the diagnosis and prognosis of cancer. In addition, CTSK has been shown to be regulated by a variety of factors, including growth factors, hormones, and environmental factors, which makes it an attractive target for researchers who are interested in the development of new biomarkers or diagnostic tools.

Overall, CTSK is a protein that has important roles in the regulation of cell-cell adhesion and cell proliferation, and has been implicated in a variety of diseases. While further research is needed to fully understand its functions and potential drug targets, CTSK is an promising target for the development of new treatments for a variety of diseases.

Protein Name: Cathepsin K

Functions: Thiol protease involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation. Involved in the release of thyroid hormone thyroxine (T4) by limited proteolysis of TG/thyroglobulin in the thyroid follicle lumen (PubMed:11082042)

The "CTSK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTSK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets